Prevalence and breakdown of non-small cell lung cancer BRAF driver mutations in a large UK cohort

Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries

“…Mutations in V-raf murine sarcoma viral oncogene homolog B1 (BRAF) occur in approximately 2–4% of patients with NSCLC. 13 , 32 , 33 Among these mutations, missense mutations at codon 600 of BRAF (known as V600 mutations) account for around 40% of all BRAF mutations in NSCLC. These BRAF V600 mutations are classified as class I BRAF mutations, as they lead to increased BRAF kinase activity that is not dependent on BRAF dimerization or activation of RAS.…”

“… 32 In 2017, the EMA approved the use of dabrafenib in combination with trametinib for the treatment of advanced NSCLC patients with V600 mutations in BRAF . 33 However, it is important to note that there is currently no EMA approval for the use of combined BRAF and MEK inhibition in NSCLC with class II (RAS-independent dimerization) or class III (RAS-dependent dimerization with CRAF) BRAF driver mutations. These different classes of BRAF mutations have distinct molecular characteristics and response profiles to targeted therapies.…”